Biota Announces Relenza Royalty for March 2011 quarter
April 28 2011 - 8:00AM
Business Wire
Biota Holdings Limited (ASX:BTA) advises that it has received
written notification from GlaxoSmithKline that Relenza sales were
$14.1 million and indicative royalties were $1.0 million, for the
three months ended 31 March 2011. The figures were calculated on an
Australian dollar exchange rate of 1.5576 to the UK pound, although
the actual payment will be calculated on exchange rates at 30 April
2011.
Indicative Relenza royalty income for the nine months to 31
March 2011 is $4.3 million.
About Biota
Biota is a leading anti-infective drug development company based
in Melbourne Australia, with key expertise in respiratory diseases,
particularly influenza. Biota developed the first-in-class
neuraminidase inhibitor, zanamivir, subsequently marketed by
GlaxoSmithKline as Relenza. Biota research breakthroughs include a
series of candidate drugs aimed at treatment of respiratory
syncytial virus (RSV) disease and Hepatitis C (HCV) virus
infections. Biota has clinical trials underway with its lead
compound for human rhinovirus (HRV) infection in patients with
compromised respiration or immune systems.
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza anti-virals, of which the lead product
lnavir®, is approved for marketing in Japan.
Relenza™ is a registered trademark of the GlaxoSmithKline group
of companies.
Inavir® is registered to Daiichi Sankyo.
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biota Fpo (Australian Stock Exchange): 0 recent articles
More Biota Holdings Limited News Articles